| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Google, Mayo Clinic build new type of AI algorithm to map interactions between areas of the brain After Moderna contamination mess, Takeda strikes deal with Japan to supply Novavax COVID-19 vaccines Providence invests $220M to bolster, retain workforce amid nationwide labor shortage Exelixis stunned by death of Chief Medical Officer Schwab, sales lead Berndt COVID-19 tracker: AZ CEO pushes back against boosters; Extra Moderna jab may not come right away, Fauci says CDC: 'Perfect storm' fueled a spike in healthcare-associated infections in 2020 Pharmas with up-and-coming JAK inhibitors face 'shrinking' potential after FDA crackdown Roche's Polivy to hit $2.4B as doctors expect 'significant switching' in newly diagnosed lymphoma: analyst Blue Cross NC, NC State team on diabetes prevention program Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028 Featured Story | By Andrea Park The new algorithm could help guide placement of brain-stimulating devices to treat neurological conditions ranging from epilepsy to Parkinson’s disease to obsessive compulsive disorder. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy With Moderna's COVID-19 vaccine facing questions in Japan because of contamination incidents, its distribution partner in the country, Takeda, is firming up plans to manufacture and distribute the yet-to-be-approved Novavax vaccine. Japan has just agreed to purchase 150 million Novavax vaccine doses. read more By Dave Muoio From sign-on incentives to organization-wide bonuses, the large nonprofit system is looking to head off a nationwide shortage of healthcare employees that has left many organizations struggling to treat an influx of COVID-19 patients. read more By Ben Adams Oncology biotech Exelixis is mourning the deaths of two key members of its company after losing its sales leader and CMO in the same week. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner In contrast with other leading pharma CEOs, AstraZeneca's top executive says an extra vaccine booster may not be necessary for the general public at the moment. Infectious disease expert Dr. Anthony Fauci maintained that a booster of Pfizer's BioNTech-partnered jab may be the only one ready by Sept. 20. Plus more headlines. read more By Dave Muoio Between the heavy use of catheters and ventilators and industry-wide shortages of staff and supplies, the COVID-19 pandemic reversed years of progress in reducing preventable hospital infections, according to a new CDC analysis of national surveillance data. read more By Kyle LaHucik With new FDA safety restrictions on JAK inhibitors—specifically Pfizer's Xeljanz, AbbVie’s Rinvoq and Lilly’s Olumiant—the next generation of JAK therapies could face an uphill battle to the finish line. read more By Angus Liu Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst is backing up that estimate with positive doctor feedback. read more By Paige Minemyer Similar programs have reduced the risk of developing type 2 diabetes by 58%, Blue Cross NC said. read more By Eric Sagonowsky As a top-selling drug worldwide, Pfizer and Bristol Myers Squibb’s Eliquis is a major target for generic players looking to steal branded sales. But with a new court win, the partners are set for many more years of exclusivity in the lucrative U.S. market. read more |
